Higher-dose Spinraza Trial Now Enrolling Part B After No Safety Issues Found

SMA News Today’s multimedia associate, Price Wooldridge, discusses a higher dose Spinraza trial now enrolling Part B after no safety issues were found. Also, DeAnn Runge shares her personal experience after switching from Spinraza to Evrysdi. Are you interested in learning more about spinal muscular atrophy? If so, please visit https://smanewstoday.com/